Scott C, Juechter L, Rocha J, Jones L, Outten B, Aishman T
J Phys Chem B. 2024; 129(1):71-87.
PMID: 39699881
PMC: 11726672.
DOI: 10.1021/acs.jpcb.4c05214.
Siamidi A, Dedeloudi A, Vlachou M
Polymers (Basel). 2021; 13(9).
PMID: 33946250
PMC: 8125139.
DOI: 10.3390/polym13091456.
Victorri-Vigneau C, Spiers A, Caillet P, Bruneau M, Ignace-Consortium , Challet-Bouju G
Curr Neuropharmacol. 2017; 16(10):1418-1432.
PMID: 28721822
PMC: 6295935.
DOI: 10.2174/1570159X15666170718144058.
Moghaddas A, Dianatkhah M, Ghaffari S, Ghaeli P
Iran J Psychiatry. 2017; 12(2):142-146.
PMID: 28659987
PMC: 5483240.
Mallik A, Chanda M, Levitin D
Sci Rep. 2017; 7:41952.
PMID: 28176798
PMC: 5296903.
DOI: 10.1038/srep41952.
Conceptualizing the neurobiology of non-suicidal self-injury from the perspective of the Research Domain Criteria Project.
Westlund Schreiner M, Klimes-Dougan B, Begnel E, Cullen K
Neurosci Biobehav Rev. 2015; 57:381-91.
PMID: 26424412
PMC: 5549671.
DOI: 10.1016/j.neubiorev.2015.09.011.
Naltrexone treatment reverses astrocyte atrophy and immune dysfunction in self-harming macaques.
Lee K, Chiu K, Didier P, Baker K, MacLean A
Brain Behav Immun. 2015; 50:288-297.
PMID: 26191654
PMC: 4631668.
DOI: 10.1016/j.bbi.2015.07.017.
Getting a grip on problem gambling: what can neuroscience tell us?.
Goudriaan A, Yucel M, van Holst R
Front Behav Neurosci. 2014; 8:141.
PMID: 24904328
PMC: 4033022.
DOI: 10.3389/fnbeh.2014.00141.
Addicted to palatable foods: comparing the neurobiology of Bulimia Nervosa to that of drug addiction.
Hadad N, Knackstedt L
Psychopharmacology (Berl). 2014; 231(9):1897-912.
PMID: 24500676
PMC: 4484591.
DOI: 10.1007/s00213-014-3461-1.
Selective review and commentary on emerging pharmacotherapies for opioid addiction.
Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K
Subst Abuse Rehabil. 2014; 2:181-8.
PMID: 24474855
PMC: 3846315.
DOI: 10.2147/SAR.S22782.
Effect of opioid antagonists on sex hormone secretion.
Tenhola H, Sinclair D, Alho H, Lahti T
J Endocrinol Invest. 2011; 35(2):227-30.
PMID: 22183092
DOI: 10.3275/8181.
Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
DeFulio A, Everly J, Leoutsakos J, Umbricht A, Fingerhood M, Bigelow G
Drug Alcohol Depend. 2011; 120(1-3):48-54.
PMID: 21782353
PMC: 3245785.
DOI: 10.1016/j.drugalcdep.2011.06.023.
Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.
Everly J, DeFulio A, Koffarnus M, Leoutsakos J, Donlin W, Aklin W
Addiction. 2011; 106(7):1309-18.
PMID: 21320227
PMC: 3107896.
DOI: 10.1111/j.1360-0443.2011.03400.x.
Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence.
Suh J, Pettinati H, Kampman K, OBrien C
Am J Addict. 2008; 17(6):463-8.
PMID: 19034737
PMC: 2657877.
DOI: 10.1080/10550490802409074.
A placebo-controlled trial of modafinil for nicotine dependence.
Schnoll R, Wileyto E, Pinto A, Leone F, Gariti P, Siegel S
Drug Alcohol Depend. 2008; 98(1-2):86-93.
PMID: 18541389
PMC: 2610628.
DOI: 10.1016/j.drugalcdep.2008.04.008.
Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene.
Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A
J Neurosci. 2005; 25(5):1103-12.
PMID: 15689546
PMC: 6725961.
DOI: 10.1523/JNEUROSCI.3008-04.2005.
Choosing a behavioral therapy platform for pharmacotherapy of substance users.
Carroll K, Kosten T, Rounsaville B
Drug Alcohol Depend. 2004; 75(2):123-34.
PMID: 15276217
PMC: 3668430.
DOI: 10.1016/j.drugalcdep.2004.02.007.
Agents in development for the management of cocaine abuse.
Gorelick D, Gardner E, Xi Z
Drugs. 2004; 64(14):1547-73.
PMID: 15233592
DOI: 10.2165/00003495-200464140-00004.